Mats Jerkeman, MD, PhD, Skane University Hospital, Lund, Sweden, discusses the final results of the PHILEMON Phase II trial (NCT02460276) evaluating ibrutinib, lenalidomide and rituximab in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL). The results show a median progression-free survival of 19 months, which is comparable to ibrutinib alone. The regimen has good efficacy in patients with TP53 mutation and therefore could be a treatment option for high-risk MCL. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
